In contrast to regorafenib and sorafenib, cabozantinib has unique targets in addition to the mesenchymal-epithelial transition factor (MET) receptor and the “anexelekto” (AXL) receptor tyrosine kinase to resist antiangiogenic, especially MET has predicted value involved in HCC progression by the MET/HGF pathway (Kelley et al., 2020; Schoffski et al., 2020). Here, MET is linked to hepatocellular carcinoma.